Human CXCR1 Antibody from MYBIOSOURCE INC.

Search, find, compare suppliers for anti-Human CXCR1 antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityHuman CXCR1
Clone[7D22]
Host SpeciesMouse
Reactive Specieshuman
IsotypeIgG2
Formatunconjugated
Size0.1 mg
Concentrationn/a
ApplicationsWestern Blot (WB), Flow Cytometry (FC/FACS), Neutr
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionCXCR1, also known as IL-8 RA and CD181, is an approximately 60 kDa 7TM glycoprotein that functions as a receptor for the chemokine CXCL8/IL-8. It is expressed on neutrophils, monocytes, CD8 T cells, FoxP3+ CD4 Treg cells, mast cells, neuronal and glial cells, vascular endothelial cells, and melanoma. CXCR1 forms homodimers and heterodimers with CXCR2/IL-8 RB. It can be cleaved from neutrophils in the lungs of cystic fibrosis patients to release fragments that promote CXCL8 production from airway epithelial cells. CXCR1 mediates neutrophil activation and chemotaxis to sites of inflammation as well as angiogenesis and melanoma invasiveness.
ImmunogenAntibody Generation: This antibody was produced from a hybridoma (mouse myeloma fused with spleen cells from a mouse) immunized with human recombinant CXCR1.
Other Names[CXCR1; C-C; CD128; CD181; CKR-1; IL8R1; IL8RA; CMKAR1; IL8RBA; CDw128a; C-C-CKR-1], [CXCR1; CXCR1; C-C; CD128; CD181; CKR-1; IL8R1; IL8RA; CMKAR1; IL8RBA; CDw128a; C-C-CKR-1; CMKAR1; IL8RA; CXC-R1; CXCR-1; IL-8R A]
Gene, Accession #[CXCR1], Gene ID: 3577, NCBI: NP_000625.1, UniProt: P25024
Catalog #MBS690150
Price$490
Order / More InfoHuman CXCR1 Antibody from MYBIOSOURCE INC.
Product Specific Referencesn/a
MYBIOSOURCE INC.
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166

sales@mybiosource.com

http://www.MyBioSource.com

Profile of MYBIOSOURCE INC.
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.